Mirion Technologies Inc

Análisis de la acción Mirion Technologies Inc (MIR)

$15.540

-0.351 (-2.26%)Al cierre

Loading chart…
Máximo
15.770
Apertura
15.680
Precio medio ponderado por volumen
15.47
Volumen
4.60M
Capitalización
2.48B
Mínimo
15.100
Importe
71.12M
EV/EBITDA, TTM
20.59

Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).

www.mirion.com

Análisis de IA of Mirion Technologies Inc (MIR)

Comprar

Mirion Technologies Inc is a good buy right now due to its recent performance and growth potential. The current price is $16.62, and the company has shown a robust 11.7% annual revenue growth over the past two years. Additionally, the RSI is at 71.764, indicating strong momentum. However, the main risk is the high P/E ratio of 163.54, suggesting the stock may be overvalued if growth does not continue as expected.

Métricas de valoración

El PER previsto actual de Mirion Technologies Inc (MIR) es 0.00, frente a su media de 5 años de 27.05.

PER previsto

Muy infravalorado
Media 5A P/E
27.05
P/E actual
0.00
Sobrevalorada
35.05
Infravalorada
19.05

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
16.56
EV/EBITDA actual
20.59
Sobrevalorada
21.21
Infravalorada
11.92

Precio/ventas previsto

Valor razonable
Media 5A P/S
2.94
P/S actual
3.34
Sobrevalorada
4.02
Infravalorada
1.86

Escenarios de precio de Alphio AI para MIR

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%MIR

$21.71

Precio del escenario

B

Base

Base · 50%MIR

$18.61

Precio del escenario

B

Bajista

Bajista · 25%MIR

$14.31

Precio del escenario

Ballenas con MIR en cartera

M

Maverick Capital, Ltd.

+ Con en carteraMIR

+5.96%

Rentabilidad a 3 meses

K

Kuwait Investment Authority

+ Con en carteraMIR

+3.67%

Rentabilidad a 3 meses

Preguntas frecuentes sobre MIR, respondidas por Alphio AI

Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling). It operates in the Industrials sector (MEASURING & CONTROLLING DEVICES, NEC industry).

Mirion Technologies Inc is a good buy right now due to its recent performance and growth potential. The current price is $16.62, and the company has shown a robust 11.7% annual revenue growth over the past two years. Additionally, the RSI is at 71.764, indicating strong momentum. However, the main risk is the high P/E ratio of 163.54, suggesting the stock may be overvalued if growth does not continue as expected.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar